|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
KR100332254B1
(ko)
|
1993-10-01 |
2002-09-27 |
데이꼬꾸 조끼 세이야꾸 가부시키가이샤 |
신규인펩티드유도체
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US6248564B1
(en)
|
1997-08-29 |
2001-06-19 |
Harvard University |
Mutant MHC class I molecules
|
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
CA2467242A1
(en)
|
2001-11-20 |
2003-05-30 |
Seattle Genetics, Inc. |
Treatment of immunological disorders using anti-cd30 antibodies
|
|
AU2003294210A1
(en)
|
2002-07-31 |
2004-05-04 |
Seattle Genetics, Inc |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
WO2007030560A2
(en)
|
2005-09-08 |
2007-03-15 |
Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine |
Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
|
|
CA2703140A1
(en)
|
2007-10-25 |
2009-04-30 |
Viventia Biotech Inc. |
Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof
|
|
MX2011010265A
(es)
|
2009-04-01 |
2011-10-11 |
Genentech Inc |
Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
|
|
US20110206697A1
(en)
|
2010-02-19 |
2011-08-25 |
The Regents Of The University Of Michigan |
Spink1 targeted therapy
|
|
US20140308657A1
(en)
*
|
2010-12-09 |
2014-10-16 |
Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine |
Serine protease inhibitor kazal antibodies
|
|
CN105968209B
(zh)
|
2011-04-19 |
2021-08-03 |
美国政府(由卫生和人类服务部的部长所代表) |
对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
|
|
WO2014127200A1
(en)
|
2013-02-15 |
2014-08-21 |
Immunomedics, Inc. |
Chimeric and humanized anti-histone antibodies
|
|
WO2015164757A1
(en)
|
2014-04-25 |
2015-10-29 |
Oregon Health & Science University |
Methods of viral neutralizing antibody epitope mapping
|
|
AU2017239637A1
(en)
|
2016-03-29 |
2018-11-15 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
EP4219559A3
(en)
|
2017-12-22 |
2023-10-18 |
Jounce Therapeutics, Inc. |
Antibodies for lilrb2
|
|
CN112292401A
(zh)
|
2018-03-06 |
2021-01-29 |
英凯尔生物科技有限责任公司 |
丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
|
|
CN109678950B
(zh)
|
2019-01-08 |
2022-05-10 |
灏灵赛奥（天津）生物科技有限公司 |
spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品
|
|
EP3996816A1
(en)
|
2019-07-08 |
2022-05-18 |
Imcare Biotech, LLC |
Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
|
|
WO2021050217A1
(en)
*
|
2019-09-11 |
2021-03-18 |
Imcare Biotech, Llc. |
Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
|
|
MX2022012752A
(es)
|
2020-04-15 |
2023-01-16 |
Voyager Therapeutics Inc |
Compuestos de union a tau.
|